bezafibrate has been researched along with Coronary Heart Disease in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.25) | 18.7374 |
| 1990's | 26 (37.68) | 18.2507 |
| 2000's | 35 (50.72) | 29.6817 |
| 2010's | 3 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D | 1 |
| Behar, S; Benderly, M; Boyko, V; Goldenberg, I; Sidi, R; Tanne, D; Tenenbaum, A | 1 |
| Benderly, M; Boyko, V; Goldbourt, U | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
| Adler, Y; Behar, S; Boyko, V; Goldbourt, U; Haim, M; Matetzky, S; Mekori, YA; Reshef, T; Tanne, D | 1 |
| Aoyagi, K; Fujimori, Y; Hirose, J; Hitsumoto, T; Kaku, M; Kanai, M; Kawamura, K; Morio, H; Noike, H; Ohsawa, H; Ohshima, T; Ozegawa, M; Sakuragawa, H; Sakurai, T; Sato, S; Terasawa, K; Tokuhiro, K; Uchida, Y; Yamada, K; Yoshinaga, K | 1 |
| Ishibashi, S | 1 |
| Cook, C; Cooper, J; Meade, T; Zuhrie, R | 1 |
| Matsuzawa, Y; Nagai, Y; Takemura, K; Yamashita, S; Yanagi, K | 1 |
| Boden, WE | 1 |
| Behar, S; Boyko, V; Fisman, EZ; Leor, J; Mandelzweig, L; Motro, M; Tenenbaum, A | 1 |
| Arcavi, L; Behar, S; Boyko, V; Caspi, A; Knobler, H; Reshef, N | 1 |
| Battler, A; Behar, S; Boyko, V; Goldbourt, U; Haim, M | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A | 1 |
| Fisman, EZ; Motro, M; Tenenbaum, A | 1 |
| Behar, S; Boyko, V; Goldbourt, U; Goldenberg, I; Reicher-Reiss, H | 1 |
| Behar, S; Boyko, V; Brunner, D; Doolman, R; Goldbourt, U; Haim, M; Sela, BA; Tanne, D | 1 |
| Battler, A; Behar, S; Benderly, M; Boyko, V; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R | 1 |
| Goldbourt, U; Koren-Morag, N; Tanne, D | 1 |
| Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R | 1 |
| Charach, G; Grosskopf, I; Iaina, A; Judevices, R; Mor, R; Rubinstein, A; Weintraub, MS; Wollman, Y | 1 |
| Hess, OM; Seiler, C; Suter, TM | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Schonfeld, G | 1 |
| Barasch, E; Behar, S; Benderly, M; Caspi, A; Goldbourt, U; Graff, E; Pelled, B; Reicher-Reiss, H; Reisin, L; Roguin, N | 1 |
| Dujovne, CA; Lozada, A | 1 |
| Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H; Shotan, A | 1 |
| Ishiwata, S; Nakanishi, S; Nishiyama, S; Seki, A | 1 |
| Behar, S; Benderly, M; Boyko, V; Brunner, D; Graff, E; Reicher-Reiss, H; Shotan, A | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B | 1 |
| Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P | 1 |
| Ector, H | 1 |
| Kesäniemi, YA | 1 |
| Dhanjil, S; Diamond, JR; Elkeles, RS; Feher, MD; Mahmood, S; Mather, H; Nicolaides, AN; Poulter, C; Richmond, W; Sharp, P | 1 |
| Kanaki, T; Saito, Y | 1 |
| Behar, S | 1 |
| Rader, DJ | 1 |
| Behar, S; Benderly, M; Brunner, D; Goldbourt, U; Graff, E; Haim, M; Reicher-Reiss, H | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, F; Cortellaro, M; Mancini, M; Mariani, M; Paoletti, R | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Jones, PH | 1 |
| Brinton, EA; Krakoff, J; Vela, BS | 1 |
| Isles, CG; Paterson, JR | 1 |
| Durrington, P | 1 |
| Oboubie, K; Ogunko, A | 1 |
| Miller, M | 1 |
| Duriez, P; Fruchart, JC | 1 |
| Vita, JA; Winniford, M; Yeung, AC | 1 |
| Hirschfield, G | 1 |
| Barter, PJ; Dimmitt, SB; Watts, GF | 1 |
| Robinson, S; Valabhji, J | 1 |
| Tada, N | 1 |
| Mikhailidis, DP; Rizos, E | 2 |
| Goldbourt, U; Graff, E; Koren-Morag, N; Tanne, D | 2 |
| Kamaliah, MD; Sanjay, LD | 1 |
| Betteridge, DJ | 1 |
| Behar, S; Boyko, V; Goldbourt, U; Haim, M; Leor, J; Mekori, YA; Reshef, T; Tanne, D | 1 |
| Kudlacek, P; Sinzinger, H; Virgolini, I | 1 |
| Chan, MK | 1 |
| Cramb, R; Florkowski, CM; Hughes, EA; Jones, AF | 1 |
| Green, KG; Heady, A; Oliver, MF | 1 |
| Abshagen, U; Baldamus, CA; Grützmacher, P; Lang, PD; Radtke, HW; Scheuermann, EH; Schoeppe, W; Siede, W | 1 |
| Di Biase, L; Neuman, J; Neuman, MP | 1 |
22 review(s) available for bezafibrate and Coronary Heart Disease
| Article | Year |
|---|---|
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2015 |
[Guideline for management of lipid metabolism].
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Primary Prevention; Risk; Simvastatin | 2002 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Probucol; Risk Factors | 1994 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome | 2004 |
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Triglycerides | 2005 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fibric Acids; Gemfibrozil; Hemostasis; Humans; Hypolipidemic Agents; Lipoproteins; Risk Factors | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids | 1994 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
[Anti-atherogenic drugs].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Bezafibrate; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Probucol; Recurrence; Syndrome | 1998 |
Pathophysiology and management of low high-density lipoprotein cholesterol.
Topics: Animals; Bezafibrate; Cholesterol, HDL; Coronary Disease; Diet; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Life Style; Lipoproteins, HDL; Male; Middle Aged; Risk Factors | 1999 |
Fibrates and high-dose statins to prevent coronary heart disease events.
Topics: Angioplasty, Balloon, Coronary; Bezafibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Myocardial Revascularization; Randomized Controlled Trials as Topic; Triglycerides | 1999 |
The role of fibric acid derivatives in the secondary prevention of coronary heart disease.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides | 2000 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Triglycerides | 2000 |
New developments in the treatment of low high-density lipoprotein cholesterol.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Risk Factors | 1999 |
Recent developments in the treatment of hypertriglyceridemia.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents | 1999 |
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents | 2001 |
[Overviews of fibrate].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Topics: Adult; Bezafibrate; Biomarkers; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Triglycerides | 2001 |
Lipid-lowering trials in diabetes.
Topics: Arteriosclerosis; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male | 2001 |
Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.
Topics: Bezafibrate; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Risk Factors; Triglycerides | 2002 |
23 trial(s) available for bezafibrate and Coronary Heart Disease
| Article | Year |
|---|---|
Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Topics: Aged; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Israel; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Survival Rate; Time Factors | 2009 |
Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.
Topics: Angioscopy; Bezafibrate; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Disease; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Triglycerides | 2002 |
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arteries; Bezafibrate; Coronary Disease; Double-Blind Method; Humans; Leg; Male; Middle Aged; Peripheral Vascular Diseases; Stroke; Treatment Outcome | 2002 |
High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Disease; Diabetes Complications; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Proportional Hazards Models | 2004 |
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Topics: Aged; Bezafibrate; Cholesterol, HDL; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Triglycerides | 2006 |
Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.
Topics: Bezafibrate; Case-Control Studies; Coronary Disease; Death, Sudden, Cardiac; Female; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors | 2007 |
C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Death, Sudden, Cardiac; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Recurrence; Risk Factors | 2007 |
Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.
Topics: Aged; Bezafibrate; Brain Ischemia; Confidence Intervals; Coronary Disease; Female; Follow-Up Studies; Heart Rate; Humans; Hypolipidemic Agents; Incidence; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Societies, Medical; Time Factors | 2008 |
Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Chylomicrons; Coronary Artery Disease; Coronary Disease; Diterpenes; Eating; Fasting; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Lipoproteins; Male; Middle Aged; Retinyl Esters; Triglycerides; Vitamin A | 1995 |
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Topics: Age Factors; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Fibrinogen; Humans; Hypertension; Israel; Male; Middle Aged; Motor Activity; Multivariate Analysis; Myocardial Infarction; Risk Factors; Sex Factors; Smoking; Triglycerides | 1995 |
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Aged; Bezafibrate; Case-Control Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Time Factors | 1996 |
Prevention of restenosis by bezafibrate after successful coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Bezafibrate; Cholesterol, HDL; Constriction, Pathologic; Coronary Disease; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Recurrence; Treatment Outcome; Triglycerides | 1995 |
Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group.
Topics: Adult; Aged; Bezafibrate; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Hypolipoproteinemias; Male; Middle Aged; Risk; Survival Analysis; Triglycerides | 1997 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).
Topics: Adult; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Diet, Fat-Restricted; Disease Progression; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Risk Factors; Time Factors | 1997 |
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Topics: Adult; Aged; Bezafibrate; Carotid Arteries; Cholesterol; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Exercise Test; Female; Femoral Artery; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Placebos; Time Factors; Triglycerides; Ultrasonography | 1998 |
Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention.
Topics: Aged; Bezafibrate; Coronary Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 1999 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Trea
Topics: Adult; Aged; Bezafibrate; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Tissue Plasminogen Activator; Treatment Outcome | 2000 |
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
Topics: Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol, HDL; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Survival Analysis; Treatment Outcome; Triglycerides | 2000 |
Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry.
Topics: Adult; Aged; Bezafibrate; Brain Ischemia; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Coronary Disease; Follow-Up Studies; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Lovastatin; Middle Aged; Multivariate Analysis; Odds Ratio; Registries; Risk Factors; Survival Analysis; Time Factors | 2002 |
[Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type V; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Triglycerides | 1991 |
25 other study(ies) available for bezafibrate and Coronary Heart Disease
| Article | Year |
|---|---|
Relation of body mass index to mortality among men with coronary heart disease.
Topics: Aged; Bezafibrate; Body Mass Index; Chronic Disease; Comorbidity; Coronary Disease; Data Interpretation, Statistical; Humans; Hypolipidemic Agents; Israel; Male; Middle Aged; Randomized Controlled Trials as Topic; Registries; Risk Factors | 2010 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |
Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.
Topics: Bezafibrate; Biomarkers; Brain Ischemia; Case-Control Studies; Chronic Disease; Cohort Studies; Comorbidity; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Israel; Logistic Models; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Risk Factors; Stroke | 2002 |
Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Bezafibrate; Cause of Death; Clinical Trials as Topic; Comorbidity; Coronary Disease; Cross-Sectional Studies; Female; Follow-Up Studies; Heart Failure; Humans; Israel; Male; Mathematical Computing; Middle Aged; Myocardial Infarction; Patient Selection; Risk Factors | 2003 |
Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study.
Topics: Bezafibrate; Coronary Disease; Female; Humans; Hypolipidemic Agents; Leukocyte Count; Male; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Risk Factors | 2004 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Triglycerides | 1980 |
Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate.
Topics: Bezafibrate; Cholesterol; Coronary Angiography; Coronary Disease; Coronary Vessels; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Physical Exertion; Vasodilation | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Low total cholesterol and high total mortality in patients with coronary heart disease.
Topics: Bezafibrate; Coronary Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Patient Selection; Survival Analysis | 1997 |
Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Confounding Factors, Epidemiologic; Coronary Disease; Female; Humans; Hypolipidemic Agents; Israel; Male; Middle Aged; Multivariate Analysis; Registries; Risk; Risk Factors; Survival Rate; Triglycerides | 1999 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Therapy and clinical trials.
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hypolipidemic Agents | 2000 |
Coronary artery reactivity after treatment with simvastatin.
Topics: Amlodipine; Bezafibrate; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Humans; Male; Myocardial Infarction; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Simvastatin; Survival Rate; Treatment Outcome | 2001 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.
Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Models, Statistical | 2001 |
Diabetes and lipids - a conundrum.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.
Topics: Age Factors; Aged; Bezafibrate; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Lipids; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Randomized Controlled Trials as Topic; Registries; Risk Factors; Triglycerides | 2001 |
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Male; Rhabdomyolysis | 2001 |
Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study.
Topics: Bezafibrate; Case-Control Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Time Factors | 2002 |
Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Bezafibrate; Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Diabetes Complications; Drug Evaluation; Female; Humans; Hypertriglyceridemia; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Muscular Diseases; Peritoneal Dialysis, Continuous Ambulatory | 1990 |
Bezafibrate in the treatment of hypercholesterolaemia in post-menopausal women.
Topics: Adult; Aged; Bezafibrate; Coronary Disease; Female; Humans; Hypercholesterolemia; Menopause; Middle Aged | 1990 |
Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
Topics: Bezafibrate; Clofibrate; Coronary Disease; Fibrinogen; Humans; Hypertension; Male; Smoking; World Health Organization | 1989 |
[Diabetes and hyperlipidemia. Increased coronary risk can be prevented].
Topics: Bezafibrate; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias | 1988 |
Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.
Topics: Administration, Oral; Adult; Aged; Bezafibrate; Cholesterol; Coronary Disease; Female; Half-Life; Humans; Hyperlipoproteinemia Type IV; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Triglycerides | 1986 |
Effect of bezafibrate on low levels of high density lipoprotein cholesterol in normolipidemia. Study in coronary patients and their first degree relatives.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol, HDL; Coronary Disease; Female; Humans; Lipids; Male; Middle Aged | 1986 |